Five Prime Therapeutics, Inc. (FPRX)
| Market Cap | 1.74B |
| Revenue (ttm) | 17.10M |
| Net Income (ttm) | -94.83M |
| Shares Out | 35.52M |
| EPS (ttm) | -2.68 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $37.76 |
| Previous Close | $37.76 |
| Change ($) | 0.00 |
| Change (%) | 0.00% |
| Day's Open | 37.80 |
| Day's Range | 37.13 - 37.95 |
| Day's Volume | 6,797,777 |
| 52-Week Range | 1.75 - 38.18 |
Five Prime Therapeutics (FPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
NEW YORK, March 5, 2021 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018 and 2019 ISS Securities...
Five Prime Therapeutics (FPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into fu...
NEW YORK, March 4, 2021 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Five Prime Therapeutics, Inc....
MILWAUKEE, March 4, 2021 /PRNewswire/ -- Ademi LLP is investigating Five Prime (NASDAQ: FPRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Amgen....
The big biotech wants to bolster its late-stage pipeline with a potential new stomach cancer treatment.
Five Prime Therapeutics (FPRX) stock is soaring higher on Thursday following news that Amgen (AMGN) is acquiring the company. The post FPRX Stock: The Huge Takeover News That Has Five Prime Th...
Amgen Inc (NASDAQ: AMGN) has agreed to acquire Five Prime Therapeutics Inc (NASDAQ: FPRX) for $38 per share in cash, representing an equity value of approximately $1.9 billion. The offer price...
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Five Prime Therapeutics, Inc. (NASDAQ: FPRX) to Amgen Inc. for $38.00 per s...
Amgen said Thursday it will spend $1.9 billion to buy Five Prime Therapeutics, a small biotech company with a promising stomach cancer drug. The news sent FPRX stock rocketing.
THOUSAND OAKS, Calif. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--AMGEN TO ACQUIRE FIVE PRIME THERAPEUTICS FOR $1.9 BILLION IN CASH
Five Prime Therapeutics (FPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics Announces Timing of Its Fourth Quarter 2020 and Full Year Results Conference Call
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics to Participate in the Cowen 41st Annual Health Care Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics to Participate in the SVB Leerink 10th Annual Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics to Participate in Guggenheim Healthcare Talks 2021: Oncology Day
This tiny biotech might be developing a major new cancer drug.
Biotech investors had more than just vaccines to think about this year.
There are plenty of healthcare stocks that have seen share growth this year. Here are three lesser-known stocks that have the potential to continue that growth this month and beyond.
Five Prime Therapeutics declared outstanding results last month and went up nearly 400%. Given the market potential, there may still be considerable upside.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Announces Closing of Upsized Public Offering of Common Stock
Aptose Biosciences and Five Prime Therapeutics both have explosive growth potential.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics, Inc. (Nasdaq: FPRX), announced today the pricing of an underwritten public offering of 7,200,000 shares of its common sto...
Five Prime Therapeutics stock popped for a second day running Thursday after the small biotech company unveiled promising preclinical data for an experimental cancer treatment. The post Small ...
Investors need to pay close attention to Five Prime (FPRX) stock based on the movements in the options market lately.
The stock price of Five Prime Therapeutics Inc (NASDAQ: FPRX) has increased by 237.08% on Wednesday. These are the details.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Announces Proposed Public Offering of Common Stock
And as a bonus, find out which much-loved stock let its shareholders down.
Shares of FPRX stock are skyrocketing on Wednesday after the company reported positive results from its stomach cancer treatment trial. The post Five Prime Therapeutics: 6 Things for FPRX Stoc...
With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 ...
Five Prime Therapeutics Inc. (NASDAQ: FPRX) shares more than tripled on Wednesday after the company announced positive topline results from its gastric cancer study.
Shares of Five Prime Therapeutics skyrocketed early Wednesday after the tiny biotech stock's stomach cancer treatment, a drug known as bemarituzumab, passed muster in a midstage test. The post...
Five Prime Therapeutics Inc (NASDAQ: FPRX) shares are seeing astronomical gains Wednesday in reaction to a positive data readout. What Happened: Bemarituzumab, a targeted therapy, in combinati...
A potential breakthrough in the treatment of stomach cancer helped boost shares of Five Prime Therapeutics higher by as much as 386% to $26.00 in Tuesday pre-market trades. The small-cap biote...
The biotech's stomach cancer drug hit the mark in a midstage trial.
Shares of Five Prime Therapeutics Inc. blasted 353% higher on heavy volume toward a three-year high in premarket trading Wednesday, after the company said its treatment for gastric cancer met ...
Shares of Five Prime Therapeutics Inc. blasted 314% higher in premarket trading Wednesday, after the company said its treatment for gastric cancer met all three of its efficacy endpoints from ...
Five Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q3 2020 Results - Earnings Call Transcript
Five Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q3 2020 Results - Quick Version Earnings Call Transcript
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of -21.31% and -41.49%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead...
Shares of Five Prime Therapeutics (NASDAQ:FPRX) were unchanged in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share increased 28.16% over the pas...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics Reports Third Quarter 2020 Results
Five Prime Therapeutics (FPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics Announces Timing of Its Third Quarter 2020 Results Conference Call
Five Prime (FPRX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Five Prime Therapeutics to Participate in the 2020 Wells Fargo Virtual Healthcare Conference
Five Prime Therapeutics, Inc. (FPRX) CEO Tom Civik on Q2 2020 Results - Earnings Call Transcript
Five Prime Therapeutics (FPRX) delivered earnings and revenue surprises of 31.43% and -22.76%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for t...
About FPRX
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of innovative protein therapeutics. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b, which is in Phase 3 clinical trials to treat patients with gastric or gastroesophageal junction and GEJ cancer; and FPA150, a CD8 T cell checkpoint inhibitor antibody that is in Phase 1a/1b clinical trial that targets B7-H4 in various cancers, as well as FPT155, a solub... [Read more...]
| Industry Biotechnology | IPO Date Sep 18, 2013 |
| CEO Thomas Civik | Employees 87 |
| Stock Exchange NASDAQ | Ticker Symbol FPRX |
Financial Performance
In 2019, FPRX's revenue was $14.87 million, a decrease of -70.17% compared to the previous year's $49.87 million. Losses were -$137.20 million, -2.31% less than in 2018.
Analyst Forecasts
According to 8 analysts, the average rating for FPRX stock is "Strong Buy." The 12-month stock price forecast is 35.67, which is a decrease of -5.53% from the latest price.